Opinion

Video

Therapeutic Combination Therapies for Metastatic Prostate Cancer

Author(s):

Fred Saad, CQ, MD, FRCS, FCAHS

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how combining therapies like androgen receptor–targeted agents, androgen deprivation therapy, and docetaxel can potentially improve outcomes for metastatic prostate cancer patients, with treatment selection influenced by factors such as disease volume and risk level.

The above content is prompted by the following:

  • Discuss some therapeutic combinations for metastatic prostate cancer.
  • What is the general rationale for using combination therapy (eg, androgen receptor–targeted agent and/or an androgen deprivation therapy with docetaxel)?
  • How do disease volume and level of disease risk affect selection of therapy?
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
1 KOL is featured in this series.
Nicholas van AS, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Related Content
FDA approves study of Aquablation vs radical prostatectomy in prostate cancer
October 8th 2024

FDA approves study of Aquablation vs radical prostatectomy in prostate cancer

Hannah Clarke
The WATER IV PCa will assess Aquablation vs radical prostatectomy in patients with grade group 1 to 3 localized prostate cancer.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Nicolas Demogeot, MD: Impact of GETUG 14 on early-stage prostate cancer care
October 1st 2024

Nicolas Demogeot, MD: Impact of GETUG 14 on early-stage prostate cancer care

Kevin Kunzmann
Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
PBT, IMRT provide similar patient-reported outcomes for prostate cancer at 5 years
September 29th 2024

PBT, IMRT provide similar patient-reported outcomes for prostate cancer at 5 years

Kevin Kunzmann
Data from the PARTIQoL trial show no significant difference in progression-free survival, bowel function, and other patient quality-of-life measures between PBT and IMRT.
Prior local therapy does not impact mCRPC survival with ARPI treatment
September 29th 2024

Prior local therapy does not impact mCRPC survival with ARPI treatment

Kevin Kunzmann
A late-breaking abstract at ASTRO 2024 shows local therapy history does not significantly affect the risk of death in patients with mCRPC receiving an ARPI.
© 2024 MJH Life Sciences

All rights reserved.